Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

07 July 2020: Lab/In Vitro Research

Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells

Nan-Xiang Chen 1BCEF , Kun Liu 1BC , Xuan Liu 2A , Xin-Xin Zhang 1AD , Dong-yi Han 1ADF*

DOI: 10.12659/MSM.923621

Med Sci Monit 2020; 26:e923621

Table 1 Classification and application of PIs.

TypeDrug nameBinding typeTarget affinityStatus
BoronatesBortezomib (PS-341)Reversibleβ5>β1Approved by the FDA for the treatment of multiple myeloma and lymphoma
Ixazomib (MLN-9708/2238)Reversibleβ5>β1Approved by the FDA for the treatment of multiple myeloma in combination with other drugs
Delanzomib (CEP-18770)Reversibleβ5>β1Phase I and Phase II studies
SalinosporamidesMarizomib (NPI-0052)Nonreversibleβ5>β2>β1Approved by the FDA for the treatment of malignant glioma
EpoxyketonesCarfilzomib (PR171)Reversibleβ5Approved by the FDA for the treatment of multiple myeloma
Oprozomib (ONX-0912, PR-047)Nonreversibleβ5Phase I and Phase II studies

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750